Cancer Cachexia Pipeline Market Insights Report 2025 | Analysis of Over 15 Companies and 20 Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cancer Cachexia - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.

The report delivers in-depth analysis of over 15 companies and 20 pipeline drugs in the cancer cachexia landscape. It comprises both clinical and nonclinical stage product profiles. The document includes therapeutic assessments by product type, development stage, administration route, and molecule type. It also highlights inactive pipeline products in this area.

Cancer cachexia is a multifactorial syndrome causing progressive skeletal muscle mass loss, often paired with systemic inflammation and altered metabolism. It's prevalent in advanced-stage cancers like pancreatic, gastric, lung, and colorectal, significantly impacting patient morbidity and mortality. Characterized by an inflammatory response, altered metabolism, and reduced food intake, it leads to debilitating weight loss, muscle atrophy, and fatigue. Traditional nutritional support proves inadequate, necessitating complex treatment strategies targeting both tumor and host factors.

The report uncovers the disease's pathophysiology, which involves tumor-derived molecules and host inflammatory cytokines that disrupt metabolism and appetite regulation. Cancer cachexia progresses through stages: precachexia, cachexia, and refractory cachexia, each with distinct clinical criteria. Management is multidisciplinary, comprising nutritional, pharmacological, and rehabilitative interventions. While appetite stimulants, anti-inflammatory agents, and anabolic therapies are explored, no definitive cure exists, underscoring an urgent need for innovative approaches.

The report sheds light on the cancer cachexia pipeline, profiling therapeutic candidates like FDY-8801 by Faraday Pharmaceuticals and S-oxprenolol by Actimed Therapeutics in the Phase II development stage. Other emerging therapies include GFS202A by GenFleet Therapeutics, a Phase I trial bispecific antibody, and EXT418 from Extend Biosciences, an investigational preclinical candidate.

The document categorizes approximately 20+ products by development phases such as late-stage (Phase III), mid-stage (Phase II), early-stage (Phase I), and preclinical. It also assesses the route of administration, product molecule type, and inactive candidates. Additionally, the report highlights Cancer Cachexia therapeutic advancements, collaborations, licensing activities, and acquisitions.

Insights include the pipeline analysis, unmet needs, drug impact, and therapeutic assessment. The report outlines emerging technologies addressing existing treatment limitations, key collaborations, mergers, licensing activities, and clinical study statuses. It identifies leading companies such as Genfleet Therapeutics and Faraday Pharmaceuticals at the forefront of cancer cachexia drug development.

Among the pipeline assets, key products include GFS202A, EXT418, FDY-8801, and ACM-001.1, with potential impacts on progressing therapeutic interventions in cancer cachexia management.

Key Topics Covered:

Introduction

Executive Summary

Cancer Cachexia: Overview

• Introduction
• Signs and Symptoms
• Risk Factors
• Pathophysiology
• Diagnosis
• Treatment

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Cancer Cachexia - Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Mid Stage Products (Phase II)

• Comparative Analysis

Early Stage Products (Phase I)

• Comparative Analysis

Preclinical and Discovery Stage Products

• Comparative Analysis

Inactive Products

• Comparative Analysis

Cancer Cachexia Key Companies

Cancer Cachexia Key Products

Cancer Cachexia - Unmet Needs

Cancer Cachexia - Market Drivers and Barriers

Cancer Cachexia - Future Perspectives and Conclusion

Cancer Cachexia Analyst Views

Appendix

Companies Featured

• Genfleet Therapeutics (Shanghai) Inc.
• Extend Biosciences
• Faraday Pharmaceuticals
• Actimed Therapeutics
• Pfizer
• NGM Biopharmaceuticals
• AVEO Pharmaceuticals Inc.

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/mput3k

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.